Trinity Biotech Statistics
Total Valuation
Trinity Biotech has a market cap or net worth of $15.27 million. The enterprise value is $131.13 million.
Important Dates
The next estimated earnings date is Monday, March 23, 2026, after market close.
| Earnings Date | Mar 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Trinity Biotech has 18.71 million shares outstanding. The number of shares has increased by 171.15% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 18.71M |
| Shares Change (YoY) | +171.15% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 3.02% |
| Owned by Institutions (%) | 5.11% |
| Float | 14.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.41 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.03
| Current Ratio | 1.03 |
| Quick Ratio | 0.47 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.20 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -9.46% |
| Return on Invested Capital (ROIC) | -24.82% |
| Return on Capital Employed (ROCE) | -21.99% |
| Weighted Average Cost of Capital (WACC) | 8.44% |
| Revenue Per Employee | $121,122 |
| Profits Per Employee | -$91,910 |
| Employee Count | 401 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 1.50 |
Taxes
In the past 12 months, Trinity Biotech has paid $958,000 in taxes.
| Income Tax | 958,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.17% in the last 52 weeks. The beta is 0.56, so Trinity Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | -38.17% |
| 50-Day Moving Average | 0.89 |
| 200-Day Moving Average | 0.91 |
| Relative Strength Index (RSI) | 47.88 |
| Average Volume (20 Days) | 297,262 |
Short Selling Information
| Short Interest | 351,456 |
| Short Previous Month | 408,234 |
| Short % of Shares Out | 0.67% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.61 |
Income Statement
In the last 12 months, Trinity Biotech had revenue of $48.57 million and -$36.86 million in losses. Loss per share was -$1.49.
| Revenue | 48.57M |
| Gross Profit | 17.87M |
| Operating Income | -15.22M |
| Pretax Income | -35.33M |
| Net Income | -36.86M |
| EBITDA | -14.03M |
| EBIT | -15.22M |
| Loss Per Share | -$1.49 |
Full Income StatementBalance Sheet
The company has $1.34 million in cash and $117.20 million in debt, with a net cash position of -$115.86 million or -$6.19 per share.
| Cash & Cash Equivalents | 1.34M |
| Total Debt | 117.20M |
| Net Cash | -115.86M |
| Net Cash Per Share | -$6.19 |
| Equity (Book Value) | -54.72M |
| Book Value Per Share | -2.93 |
| Working Capital | 1.02M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$1.10 million and capital expenditures -$256,000, giving a free cash flow of -$1.36 million.
| Operating Cash Flow | -1.10M |
| Capital Expenditures | -256,000 |
| Free Cash Flow | -1.36M |
| FCF Per Share | -$0.07 |
Full Cash Flow StatementMargins
Gross margin is 36.78%, with operating and profit margins of -31.33% and -75.88%.
| Gross Margin | 36.78% |
| Operating Margin | -31.33% |
| Pretax Margin | -72.73% |
| Profit Margin | -75.88% |
| EBITDA Margin | -28.88% |
| EBIT Margin | -31.33% |
| FCF Margin | n/a |
Dividends & Yields
Trinity Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -171.15% |
| Shareholder Yield | -171.15% |
| Earnings Yield | -241.37% |
| FCF Yield | -8.90% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 23, 2024. It was a reverse split with a ratio of 1:5.
| Last Split Date | Feb 23, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
Trinity Biotech has an Altman Z-Score of -1.28 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.28 |
| Piotroski F-Score | 2 |
